Deutsche medizinische Wochenschrift
-
Dtsch. Med. Wochenschr. · Apr 2021
[When to test in biomarker-stratified therapy of non-small cell lung cancer - Biomarker-stratified therapy of Non-small cell lung cancer: when and what to test?]
Therapy of non-small cell lung cancer (NSCLC) should be based on biomarker test results in the palliative setting. To this end, testing of all patients in stage IV and in the future also in the earlier stages will be important. In a conference with the patronage of the German Cancer Society, the question of "reflex testing", i.e. independently of tumor stage, was discussed but not deemed to be acceptable. The current report summarizes the results of the consensus conference and discusses possible paths to efficent biomarker testing in NSCLC.
-
A common intuition says the death of a younger person is more tragic, since older people could already live through more "innings" of their life. The most important reason against using age as a criterion in triage is however the infinite value of the other: In a relationship of responsibility and care, which is the functional base of medicine also in situations of emergency, the life of each other has infinite value, and therefore cannot be weighed against each other.
-
Fluid therapy is one of the basic and most frequently performed medical therapies in everyday clinical practice. However, optimal volume management is a challenge: the application is simple, but the whole volume management is a complex process and physicians have to pay attention on underlying pathophysiology. ⋯ Nowadays, crystalloid solutions are widely used and the standard is a balanced electrolyte solution. Only in selected situations 0,9 % sodium chloride solutions should be used, because they contain a high chloride concentration (154 mmol/l) and lead to increased risk of hyperchloremic metabolic acidosis.